***See editorial vol. 24: 1202--1203***

Introduction
============

Previous clinical studies have provided considerable evidence for a relationship between obesity and thrombosis, citing the enhanced expression of prothrombotic molecules, including plasminogen activator inhibitor-1 and tissue factor, and increased platelet activation^[@bib1])^. Additionally, it has been shown that the acceleration of thrombin action is associated with the development of insulin resistance, leading to metabolic syndrome and type 2 diabetes mellitus (T2DM)^[@bib2])^. Thrombin activates platelets, vascular endothelial cells, vascular smooth muscle cells, macrophages, and fibroblasts via binding to their protease-activated receptors (PARs). PAR-1 activation by thrombin enhances procoagulation^[@bib3])^, chemoattraction^[@bib4])^, mitogenesis^[@bib5])^, and proliferation^[@bib6])^ of these cells. Gene expression of PAR-2 has been observed in adipose tissues and macrophages of humans and rats, and PAR-2 has been shown to promote inflammation and metabolic dysfunction^[@bib7])^. Taken together, the results indicated the possibility that both PAR-1 and PAR-2 have a significant role in the development of insulin resistance. We and another group of researchers demonstrated that thrombin promotes the release of inflammatory cytokines and growth factors from adipocytes and inhibits insulin-stimulated Akt phosphorylation^[@bib8],\ [@bib9])^. We also showed that argatroban, a synthetic thrombin antagonist, can ameliorate insulin resistance in type 2 diabetic *db/db* mice^[@bib8])^. Heparin cofactor II (HCII), like antithrombin, is a serine protease inhibitor (serpin) with a molecular weight of 65.6 kDa. HCII is synthesized by hepatocytes and secreted into the blood stream at a concentration of about 1.0 µmol/L^[@bib10])^. HCII, upon activation by binding to dermatan sulfate proteoglycans, specifically inhibits thrombin action in various tissue matrices. Thus, HCII can inhibit thrombin action in various tissues without affecting hemostasis. Although we previously reported that HCII protects against cardiovascular remodeling in mice and humans^[@bib11]--[@bib17])^, the role of HCII in the regulation of glucose metabolism and insulin sensitivity has not yet been determined. Therefore, the present study aimed to clarify whether HCII is involved in glucose metabolism and insulin sensitivity in humans and mice.

Materials and Methods
=====================

Subjects for Cross-Sectional Study
----------------------------------

We determined the relationship between plasma HCII activity and HbA1c levels using data sets from our previous clinical studies^[@bib11],\ [@bib13])^. Additionally, a total of 130 individuals seeking consultation regarding lifestyle-related disorders and who had never been treated with insulin were recruited from Tokushima University Hospital, Tokushima, Japan between January 2012 and May 2013. All subjects underwent a standardized interview and physical examination.

Diagnostic Criteria for Clinical Studies
----------------------------------------

Current smokers were defined as subjects who had smoked within 1 year prior to the study. Body mass index was calculated as an index of obesity, and blood pressure was measured twice and averaged. Hypertensive patients were defined as those with systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg, and individuals on antihypertensive medications. Hyperlipidemic patients were defined as those with low-density lipoprotein cholesterol (LDL-C) ≥ 140 mg/dl and/or triglyceride (TG) levels ≥ 150 mg/dl, and individuals on lipid-lowering medications. Diabetic patients were defined as individuals who were receiving oral hypoglycemic agents or individuals with glycosylated hemoglobin A1c (HbA1c) ≥ 6.5% or fasting plasma glucose (FPG) ≥ 126 mg/dl or 2 h plasma glucose ≥ 200 mg/dl during a 75 g oral glucose tolerance test. Exclusion criteria included overt cardiac failure, known malignancy, renal failure (serum creatinine ≥ 2.0 mg/dl), and malnutrition (serum albumin \< 3.0 g/dl).

Biochemical Analysis
--------------------

Before noon, overnight fasting blood samples were collected from the antecubital vein and assayed immediately for FPG, HbA1c, serum immunoreactive insulin (IRI), and serum lipid parameters including TG, HDL-C, and LDL-C. FPG and levels of TG, HDL-C, LDL-C, and creatinine were measured by enzymatic methods. HbA1c was assayed by latex agglutination. Serum IRI level was determined by the chemiluminescent enzyme immunoassay. An index of insulin resistance in the homeostasis model assessment-insulin resistance (HOMA-IR) was calculated as FPG (mg/dl) × IRI (µU/ml)/405. For the measurements of plasma HCII activities, blood was drawn as described above, collected into a tube containing 1/10 volume of 3.8% sodium citrate, and centrifuged at 2,000 × *g* for 20 min. Plasma was stored at −80°C until use. Plasma HCII activity was measured on the basis of antithrombin activity in the presence of dermatan sulfate using the Stachrom® HCII assay kit (Diagnostica Stago, France). The intra-assay and inter-assay coefficients of variation of this kit were 3.9% and 4.3%, respectively. Our study followed the institutional guidelines of Tokushima University and was approved by the Institutional Review Board of Tokushima University Hospital. The ethics committee approved this study and the participants were required to sign an informed consent form prior to inclusion in the study, in accordance with the Declaration of Helsinki.

Animal Preparations
-------------------

We used *HCII*^+/+^ and *HCII*^+/−^ 25-week-old male mice (*HCII*^+/−^; Tokushima University, Graduate School of Biomedical Sciences, Tokushima, Japan) that we previously generated^[@bib12])^. In brief, we generated *HCII*-deficient mice by targeted disruption of the *HCII* gene^[@bib12])^. *HCII*^+/−^ mice were backcrossed for 10 generations with the C57BL/6J strain^[@bib12])^. Because the homozygotic *HCII*-deficient mice were embryonic lethal, we used male heterozygote *HCII*-deficient (*HCII*^+/−^) mice and male littermate WT (*HCII*^+/+^) mice in all experiments of this study, as in our previous studies^[@bib12],\ [@bib14],\ [@bib17])^. These animals were housed in a specific pathogen-free facility under climate-controlled conditions with a 12-h light/12-h dark cycle and were provided with either a normal diet (ND) or a high-fat diet (HFD: lard 58%, fish flour 30%, defatted soybean 10%, vitamins and minerals 2%) (Oriental Yeast Co., Ltd., Tokyo, Japan) and water ad libitum.

Biochemical Analysis
--------------------

Plasma glucose levels were enzymatically measured (Wako Chemicals, Tokyo, Japan). Serum insulin levels, adiponectin levels, and leptin levels were determined using an insulin ELISA kit (Morinaga Institute of Biological Science, Inc., Japan), an adiponectin ELISA kit (Ohtsuka Pharmaceutical, Co, Ltd., Japan) and a leptin ELISA kit (Morinaga Institute of Biological Science, Inc., Japan). HOMA-IR was calculated as fasting whole blood glucose (mg/dl) × fasting serum insulin (ng/ml)/405.

Computed Tomography Scan
------------------------

The adiposity of the mice was determined using computed tomography (CT) scanning at 25 weeks of age. Mice were anesthetized with isoflurane gas, and images were acquired on a Latheta LCT-200 (Hitachi Aloka Medical, Ltd. Japan) at Tokushima Bioimaging Station, The University of Tokushima. Animals were scanned in a 48-mm-wide specimen holder with a resolution of 96 µm pixels. For all scans, the same number of views (796) was used, which represents the amount of data collected during a single 360° rotation around the object. In pilot experiments, optimal scanning conditions were evaluated for each tissue. Obtained CT images were analyzed with provided software. Density histograms of the volume within the selected range were generated, and the total volume of skeletal muscle and adipose tissue were calculated by the summation of the total density.

Adipocyte Sizing
----------------

Epididymal fat samples were fixed in osmium tetroxide (Sigma), suspended in isotonic saline, and passed through a 250-µm nylon filter to remove fibrous elements. Cells were filtered over a 25-µm nylon filter, collected in isotonic saline, and analyzed on a Coulter counter (Mulisizer III, Coulter Electronics, Fullerton, CA), as previously described^[@bib18])^. The distribution of adipocyte size was analyzed for cells ranging 25--250 µm in diameter.

Immunohistochemistry
--------------------

Mice were sacrificed by intraperitoneal injection of high-dose pentobarbital. White adipose tissues of epididymal fat were fixed overnight in 10% neutral buffered formalin, cut into 10-µm-thick cross sections, and stained with hematoxylin-eosin and F4/80 antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA). Antibody distribution was visualized with the avidin--biotin complex technique and Vector Red substrate (Vector Laboratories, Burlingame, CA). The summation of F4/80-positive cell numbers from five independent visual fields in each animal tissue was used to determine macrophage infiltration.

Quantitative Real-Time PCR and PCR Array Analysis
-------------------------------------------------

For real-time PCR analysis, epididymal fat tissues and hepatic tissues were excised. RNA extraction and reverse transcriptase-polymerase chain reactions (RT-PCR) were performed as previously described^[@bib12],\ [@bib19])^. In brief, epididymal fat tissues, hepatic tissues, and thigh skeletal muscle were homogenized in TRIzol (Invitrogen, Carlsbad, CA), and total RNA was extracted. One microgram of total RNA was used for cDNA synthesis with a QuantiTect Reverse Transcription Kit (QIAGEN, Valencia, CA), according to the manufacturer\'s instructions. The PCR mixture contained cDNA, synthesized from 2.5 ng of total RNA, 0.1 nmol/L forward and reverse primer mix, and SYBR Green (Platinum SYBR Green qPCR SuperMi-UDG, Invitrogen Carlsbad, CA). Assays were performed with a 7300 Real-Time PCR System (Applied Biosystems, Foster City, CA). Amplification consisted of one stage of 2 min at 50°C and one stage of 2 min at 95°C followed by 40 cycles of a 2-step cycle: 15 s at 95 °C and 30 s at 60 °C. Quantitative RT-PCR analysis of 84 obesity-related genes was performed using Obesity RT^2^ Profiler PCR Arrays PAMM-017Z (QIAGEN). Data analysis of the PCR array kit was performed using the manufacturer\'s integrated web-based software for the PCR Array System (http://pcrdataanalysis.sabiosciences. com/pcr/arrayanalysis.php) using ΔΔCt-based fold-change calculations. In addition, commercially available PCR primers were purchased from Perfect realtime primer (TAKARA BIO INC., Ohtsu, Japan) for *F2r, Mcp1, Tnf, Cntf, Cntfr, Pck1, G6pc*, and *Gapdh*. The transcript levels of those genes were adjusted relative to *Gapdh* expression as an internal control.

Western Blot Analysis
---------------------

For western blot analysis, murine epididymal fat tissues, hepatic tissues, and thigh skeletal muscle were excised. The phosphorylation of AMPK*α* and Akt with or without insulin stimulation (1 U/kg) was evaluated by western blot analysis. Protein extraction and western blot analysis were performed as previously described^[@bib17],\ [@bib19])^. In brief, 100-µg protein extracts from adipose tissue, hepatic tissues, and thigh skeletal muscle from *HCII*^+/+^ and *HCII*^+/−^ mice fed an ND or HFD were boiled for 5 min in Laemmli sample buffer and run on SDS-PAGE. The protein extracts were then transferred to a PVDF membrane (Millipore Corporation, Bedford, MA). The membrane was blocked for 20 min at room temperature with SuperBlock T20 TBS Blocking Buffer (Thermo Scientific, Rockford, IL). The blots were incubated overnight at 4 °C with each primary antibody, followed by incubation for 1 h with anti-rabbit secondary antibody (horseradish peroxidase-conjugated). Immunoreactive bands were visualized using enhanced chemiluminescence with ECL-PLUS reagents (GE Healthcare, Buckinghamshire, UK) and exposure to a lumino image analyzer (LAS-3000 mini) (Fujifilm Corporation, Tokyo, Japan). The signals were quantified by densitometry using ImageJ version 1.47. About 8--12 independent samples were analyzed in each group, and the phosphospecific proteins were corrected by GAPDH as an internal control. We used primary antibodies against phosphorylated Akt (Ser473), phosphorylated AMPK (Thr172), and GAPDH (Cell Signaling Technology, Beverly, MA). All experimental procedures were performed in accordance with the guidelines from and approval of the Animal Research Committee of The University of Tokushima Graduate School.

Statistical Analysis
--------------------

In the clinical study, continuous variables were averaged; values were expressed as mean ± SD or as percentages for categorical parameters. Male gender, presence of hypertension, diabetes mellitus, hyperlipidemia, and current smoking were coded as dummy variables. The degree of association among independent variables for each glucose metabolism marker was assessed by multiple regression analysis. In the animal study, values for each parameter within a group are expressed as dot plots with mean bars. The Kruskal--Wallis test was used to assess the statistical significance of quantitative data among the groups. Bonferroni-corrected Mann--Whitney *U* test or Dunn test was used for multiple comparisons. Statistical significance was set at *p* \< 0.05.

Results
=======

Plasma HCII Activity is Inversely Associated with HbA1c, FPG, and HOMA-IR in Humans
-----------------------------------------------------------------------------------

We used clinical data sets from our previous studies^[@bib11],\ [@bib13])^ and 130 newly recruited elderly Japanese subjects. The clinical characteristics of subjects from our previous studies, the present study, and the subjects in both studies are shown in **[Table 1](#T1){ref-type="table"}**, **[Supplemental Table 1](#T2){ref-type="table"}** and **[Supplemental Table 2](#T3){ref-type="table"}**. Scatter plots of plasma HCII activities and glycosylated hemoglobin A1c (HbA1c) in each of the three studies showed significant inverse relationships (**[Fig. 1A](#F1){ref-type="fig"}**, [**Supplemental Figs. 1A, 1B**, & **1C**](#F6){ref-type="fig"}); this was also found when combining data from the three studies (**[Supplemental Fig. 1D](#F6){ref-type="fig"}**). Significant inverse relationships were also found between HCII activity and FPG (**[Fig. 1B](#F1){ref-type="fig"}**), and between HCII activity and HOMA-IR (**[Fig. 1C](#F1){ref-type="fig"}**). Multiple regression analysis confirmed inverse correlations between plasma HCII activity and HbA1c, plasma HCII activity and FPG, and plasma HCII activities and HOMA-IR, even after adjustment for age, sex, and other confounding factors (**[Table 1](#T1){ref-type="table"}**).

###### Clinical characteristics of subjects and multiple regression analysis for determinants of HbA1c, FPG and HOMA-IR

  Variables               mean ± SD      HbA1c    FPG     HOMA-IR                    
  ----------------------- -------------- -------- ------- --------- ------- -------- -------
  Age (y.r.)              63.1 ± 9.9     0.018    0.053   0.482     0.037   0.008    0.487
  Male/Female (n)         60/70          −0.029   0.891   5.389     0.312   −0.052   0.844
  BMI (kg/m^2^)           24.8 ± 4.1     0.027    0.238   0.826     0.150   0.130    0.001
  SBP (mmHg)              133.9 ± 20.3   0.007    0.153   0.166     0.196   0.000    0.045
  LDL-C (mg/dl)           129.0 ± 30.5   0.004    0.212   0.072     0.321   0.004    0.311
  HDL-C (mg/dl)           61.3 ± 16.1    −0.009   0.120   −0.186    0.213   −0.014   0.060
  TG (mg/dl)              120.3 ± 69.6   0.000    0.731   0.018     0.581   0.000    0.790
  UA (mg/dl)              5.4 ± 1.4      −0.064   0.388   −1.398    0.461   −0.091   0.361
  Cre (mg/dl)             0.73 ± 0.17    −0.496   0.493   −19.329   0.293   0.202    0.830
  FPG (mg/dl)             108.6 ± 22.2                                               
  HbA1c (%)               6.2 ± 0.9                                                  
  HOMA-IR                 1.71 ± 1.68                                                
  HCII activities (%)     99.4 ± 18.4    −0.011   0.014   −0.311    0.007   −0.013   0.041
  Current Smoking (%)     10.8% (14)     −0.105   0.662   −3.999    0.541   −0.058   0.864
  Hypertension (%)        59.2% (77)     −0.090   0.673   −2.772    0.608   −0.165   0.547
  Hyperlipidemia (%)      60.8% (79)     −0.182   0.345   −2.598    0.593   −0.000   0.486
  Diabetes Mellitus (%)   30.0% (39)                                                 

BMI: body mass index, SBP: systolic blood pressure, LDL-C: low density lipoprotein cholesterol, HDL-C: high density lipoprotein cholesterol, TG: triglyceride, UA: uric acid, Cre: creatinine, FPG: fasting plasma glucose, HbA1c: glycosylated hemoglobin A1c, HOMA: homeostatic model assessment, HCII: heparin cofactor II

  Characteristics                    Total (*n* = 306)   Men (*n* = 154)   Women (*n* = 152)   *p*-value
  ---------------------------------- ------------------- ----------------- ------------------- -----------
  Age (yr)                           68.9 ± 11.1         67.2 ± 10.8       70.6 ± 11.1         \< 0.01
  Body mass index (kg/m^2^)          23.2 ± 3.7          23.6 ± 3.8        22.8 ± 3.5          NS
  SBP (mmHg)                         138.3 ± 20.2        138.2 ± 20.2      138.5 ± 20.3        NS
  Total cholesterol (mg/dL)          198.1 ± 39.6        187.3 ± 40.9      209.1 ± 35.1        \< 0.0001
  LDL-cholesterol (mg/dL)            124.5 ± 34.5        114.4 ± 35.5      134.8 ± 30.3        \< 0.0001
  HDL-cholesterol (mg/dL)            47.0 ± 13.2         44.2 ± 12.4       49.9 ± 13.4         \< 0.0005
  Triglyceride (mg/dL)               131.6 ± 85.4        143.5 ± 104.1     119.5 ± 58.8        \< 0.05
  Lipid peroxide (nmol/mL)           0.45 ± 0.23         0.48 ± 0.26       0.41 ± 0.18         \< 0.005
  Lipoprotein(a) (mg/dL)             23.0 ± 17.1         22.9 ± 15.7       23.1 ± 18.5         NS
  HbA1c (%)                          5.9 ± 1.7           6.1 ± 1.8         5.8 ± 1.6           NS
  Antithrombin activity (%)          93.1 ± 14.8         89.5 ± 14.3       96.6 ± 14.5         \< 0.0005
  Heparin cofactor II activity (%)   94.0 ± 18.3         92.1 ± 18.2       95.9 ± 18.2         NS
  Maximum plaque thickness (mm)      2.04 ± 1.13         2.15 ± 1.18       1.93 ± 1.07         NS
  Current smoking (%)                28.4                48.7              7.9                 \< 0.0001
  Hypertension (%)                   57.8                55.8              59.9                NS
  Hyperlipidemia (%)                 42.5                35.7              49.3                \< 0.05
  Diabetes mellitus (%)              30.7                36.4              25                  \< 0.05

Values are means ± SD or percentages.

Baseline characteristics were compared between men and women by unpaired *t* test or *χ*^2^ test for independence.

(Referred from the article by Aihara *et al.* Circulation. 2004; 109: 2761--2765)

  Characteristics                    ABI ≥ 0.9      ABI \< 0.9     *p*-value
  ---------------------------------- -------------- -------------- -----------
  Male/Female                        233/199        41/21          0.065
  Age (yr)                           66.4 ± 11.0    71.0 ± 9.5     0.001
  BMI (kg/m^2^)                      23.7 ± 3.5     22.4 ± 2.8     0.001
  SBP (mmHg)                         136.2 ± 20.5   143.6 ± 20.4   0.001
  LDL-cholesterol (mg/dL)            121.0 ± 35.0   129.2 ± 40.8   0.134
  HDL-cholesterol (mg/dL)            50.9 ± 16.9    50.7 ± 24.0    0.938
  Triglyceride (mg/dL)               139.4 ± 86.2   136.2 ± 78.2   0.762
  Lipoprotein(a) (mg/dL)             20.7 ± 15.8    27.0 ± 27.4    0.081
  HbA1c (%)                          6.0 ± 1.7      7.3 ± 6.7      0.148
  Antithrombin activity (%)          97.8 ± 15.8    94.7 ± 17.0    0.173
  Heparin cofactor II activity (%)   94.6 ± 17.8    87.5 ± 19.7    0.009
  Current smoking (%)                127 (29.4)     23 (41.1)      0.003
  Hypertension (%)                   266 (61.6)     46 (74.2)      0.041
  Hyperlipidemia (%)                 189 (43.4)     29 (46.8)      0.658
  Diabetes mellitus (%)              121 (28.0)     33 (53.2)      0.001

Values are means ± SD or percentages.

Baseline characteristics were compared between ABI ≥ 0.9 and ABI \< 0.9 by unpaired *t* test or *χ*^2^ test for independence.

(Referred from the article by Aihara *et al.* J Atheroscler Thromb. 2009; 16: 127--134.)

![Scatter plots of plasma HCII activity and HbA1c values (A), plasma HCII activity and FPG levels (B), and of plasma HCII activity and HOMA-IR values (C) (*n* = 130 in each panel).](jat-24-1215-g001){#F1}

![Scatter plots of plasma HCII activity and HbA1c values in our previous studies (A: *n* = 130 and B: *n* = 494), the present study (C: *n* = 130), and all studies combined (D: *n* = 930)](jat-24-1215-g006){#F6}

HFD Prominently Increases Adipocyte Size in *HCII*^+/−^ Mice
------------------------------------------------------------

To examine whether the inhibition of thrombin action by HCII plays a role in the regulation of glucose metabolism, we used *HCII*^+/−^ mice and compared their glucose metabolism with that of *HCII*^+/+^ mice. Growth curve analysis revealed no difference between *HCII*^+/+^ and *HCII*^+/−^ mice fed ND (**[Fig. 2A](#F2){ref-type="fig"}**). Both *HCII*^+/+^ and *HCII*^+/−^ mice who were fed HFD showed greater increase in body weight compared to mice who were fed ND (**[Fig. 2A](#F2){ref-type="fig"}**). Body composition assessment by CT revealed no significant differences in the volume of skeletal muscles, subcutaneous fat, and visceral fat between *HCII*^+/+^ and *HCII*^+/−^ mice ([**Figs. 2B, 2C**, & **2D**](#F2){ref-type="fig"}). On the contrary, Coulter counter analysis revealed greater adipocyte diameters in HFD-fed *HCII*^+/−^ mice than in HFD-fed *HCII*^+/+^ mice ([**Figs. 2E** & **2F**](#F2){ref-type="fig"}).

![Gross phenotype and aberrant glucose metabolism in HCII-deficient mice\
(A) Growth curve analysis after weaning in *HCII*^+/+^ and *HCII*^+/−^ mice fed ND or HFD (*n* = 18 in each group). Error bar indicates standard deviation. (B) Measurements of skeletal muscle volume, (C) subcutaneous fat volume, and (D) visceral fat volume by computed tomography scans in *HCII*^+/+^ and *HCII*^+/−^ mice fed ND or HFD (*n* = 5--6 in each group). (E) Coulter counter analysis for mean adipocyte (epididymal fat tissue) diameter measurements among the four mice groups (*n* = 4--6 in each group). (F) Representative results of Coulter counter analysis for measurements of adipocyte diameters among the four mice groups. (G) Measurements of fasting plasma glucose levels, (H) serum insulin levels and (I) HOMA-IR values in *HCII*^+/+^ and *HCII*^+/−^ mice fed ND or HFD (*n* = 16--24 in each group). Bars represent the mean values in each group. \**p* \< 0.05, \*\**p* \< 0.01](jat-24-1215-g002){#F2}

HFD-Induced Obesity Causes Greater Hyperglycemia and Hyperinsulinemia in *HCII*^+/−^ Mice
-----------------------------------------------------------------------------------------

Although no obvious difference in FPG was observed between *HCII*^+/+^ and *HCII*^+/−^ mice fed ND, higher FPG levels were observed in HFD-fed *HCII*^+/−^ mice than that in HFD-fed *HCII*^+/+^ mice (**[Fig. 2G](#F2){ref-type="fig"}**). Fasting serum insulin levels more prominently increased in *HCII*^+/−^ mice than in *HCII*^+/+^ mice in the HFD group (**[Fig. 2H](#F2){ref-type="fig"}**); this resulted in higher HOMA-IR values in *HCII*^+/−^ mice than those in *HCII*^+/+^ mice in the HFD group (**[Fig. 2I](#F2){ref-type="fig"}**). There were no significant differences in adiponectin or leptin serum levels between *HCII*^+/+^ and *HCII*^+/−^ mice in each diet group ([**Figs. 3A** & **3B**](#F3){ref-type="fig"}).

![Serum adiponectin and leptin levels, gene expression profiles, and macrophage infiltration in adipose tissues of *HCII*^+/+^ and *HCII*^+/−^ mice fed ND or HFD\
(A) Serum levels of adiponectin and (B) leptin in *HCII*^+/+^ and *HCII*^+/−^ mice fed ND or HFD (*n* = 7--10 in each group). (C) Gene expression levels of *F2r*, (D) *Mcp1*, (E) *Tnf*, (F) *Cntf*, and (G) *Cntfr* in adipose tissues of *HCII*^+/+^ and *HCII*^+/−^ mice fed ND or HFD (*n* = 6--9 in each group). (H) Representative photos of F4/80 staining and (I) quantification of total F4/80-positive cell numbers counted from the five independent visual fields in adipose tissues of *HCII*^+/+^ and *HCII*^+/−^ mice fed ND or HFD. Bars represent the mean values in each group. \**p* \< 0.05, \*\**p* \< 0.01](jat-24-1215-g003){#F3}

HFD Accelerates Inflammation and Macrophage Recruitment in the Adipose Tissue of *HCII*^+/−^ Mice
-------------------------------------------------------------------------------------------------

In the quantitative RT-PCR analysis of epididymal fat tissue, no significant difference in the gene expression levels of *F2r*, a murine homologue of thrombin receptor gene, was observed (**[Fig. 3C](#F3){ref-type="fig"}**). Because chronic inflammation in adipose tissue plays pivotal roles in the development of insulin resistance, we evaluated the gene expression levels of monocyte chemotactic protein-1 (*Mcp1*) and tumor necrosis factor (*Tnf*) in epididymal fat tissue in mice. The expression levels of *Mcp1* and *Tnf* genes significantly increased in *HCII*^+/−^ mice compared to those in *HCII*^+/+^ mice in the HFD group ([**Figs. 3D** & **3E**](#F3){ref-type="fig"}). In addition, immunohistochemical analysis revealed that F4/80 (cell-surface marker of macrophages)-positive cells were significantly increased in *HCII*^+/−^ mice fed HFD compared to other groups ([**Figs. 3H** & **3I**](#F3){ref-type="fig"}). These results are consistent with the marked enhancement of *Mcp1* and *Tnf* gene expression in *HCII*^+/−^ mice with HFD-induced obesity ([**Figs. 3D** & **3E**](#F3){ref-type="fig"}).

HCII Insufficiency Dysregulates the CNTF--CNTF Receptor Axis in Adipose Tissue of HFD-Treated Obese Mice
--------------------------------------------------------------------------------------------------------

To identify other glucose metabolism-related key molecules, we screened the gene expression profiles in HFD-treated murine adipose tissues (epididymal fat tissue) with a PCR Array System, and found that ciliary neurotrophic factor receptor (*Cntfr*) was significantly downregulated in *HCII*^+/−^ mice (**[Supplemental Table 3](#T4){ref-type="table"}**). Although *Cntf* gene expression levels did not significantly differ between *HCII*^+/+^ and *HCII*^+/−^ mice, regardless of diet (**[Fig. 3F](#F3){ref-type="fig"}**), *Cntfr* gene expression was significantly reduced in *HCII*^+/−^ mice compared to *HCII*^+/+^ mice in the HFD group (**[Fig. 3G](#F3){ref-type="fig"}**). However, in an *in vitro* study, we failed to prove that HCII and/or dermatan sulfate are able to increase both *Cntf* and *Cntfr* gene expression levels in adipocytes with statistical significance ([**Supplemental Figs. 2A** & **2B**](#F7){ref-type="fig"}). These results indicated that HCII seems to be indirectly associated with the CNTF --CNTF receptor axis *in vivo*.

                                                                                              Fold Change (comparing to HCII-WT mice fed a HFD)                     
  ----- ----------- ------------------------------------------------------------------------- --------------------------------------------------- ----------------- ----------
  A01   Adcyap1     Adenylate cyclase activating polypeptide 1                                1.3553                                              (0.00001, 2.95)   0.517354
  A02   Adcyap1r1   Adenylate cyclase activating polypeptide 1 receptor 1                     0.6598                                              (0.30, 1.02)      0.248703
  A03   Adipoq      Adiponectin, C1Q and collagen domain containing                           0.7423                                              (0.48, 1.01)      0.101473
  A04   Adipor1     Adiponectin receptor 1                                                    0.8187                                              (0.67, 0.96)      0.046135
  A05   Adipor2     Adiponectin receptor 2                                                    0.7263                                              (0.37, 1.08)      0.237507
  A06   Adra2b      Adrenergic receptor, alpha 2b                                             1.005                                               (0.42, 1.59)      0.926584
  A07   Adrb1       Adrenergic receptor, beta 1                                               1.0728                                              (0.23, 1.91)      0.752198
  A08   Agrp        Agouti related protein                                                    0.7386                                              (0.53, 0.95)      0.071847
  A09   Apoa4       Apolipoprotein A-IV                                                       0.8082                                              (0.55, 1.06)      0.207946
  A10   Atrn        Attractin                                                                 0.7263                                              (0.55, 0.90)      0.036849
  A11   Bdnf        Brain derived neurotrophic factor                                         1.3117                                              (0.75, 1.87)      0.178754
  A12   Brs3        Bombesin-like receptor 3                                                  0.8082                                              (0.55, 1.06)      0.207946
  B01   C3          Complement component 3                                                    1.2533                                              (0.86, 1.65)      0.166931
  B02   Calca       Calcitonin/calcitonin-related polypeptide, alpha                          0.7306                                              (0.36, 1.10)      0.234034
  B03   Calcr       Calcitonin receptor                                                       1.3796                                              (0.00001, 3.05)   0.518477
  B04   Cartpt      CART prepropeptide                                                        0.6637                                              (0.41, 0.92)      0.07998
  B05   Cck         Cholecystokinin                                                           3.1821                                              (0.00001, 9.22)   0.275644
  B06   Cckar       Cholecystokinin A receptor                                                1.9166                                              (0.00001, 4.61)   0.35273
  B07   Clps        Colipase, pancreatic                                                      1.417                                               (0.03, 2.80)      0.895452
  B08   Cnr1        Cannabinoid receptor 1 (brain)                                            0.9184                                              (0.56, 1.27)      0.77961
  B09   Cntfr       Ciliary neurotrophic factor receptor                                      0.4749                                              (0.29, 0.66)      0.005242
  B10   Cpd         Carboxypeptidase D                                                        1.0539                                              (0.76, 1.35)      0.666465
  B11   Cpe         Carboxypeptidase E                                                        1.0792                                              (0.56, 1.60)      0.6268
  B12   Crhr1       Corticotropin releasing hormone receptor 1                                1.2311                                              (0.00, 2.46)      0.508164
  C01   Drd1a       Dopamine receptor D1A                                                     0.4642                                              (0.12, 0.81)      0.1923
  C02   Drd2        Dopamine receptor D2                                                      0.6443                                              (0.42, 0.87)      0.043683
  C03   Gal         Galanin                                                                   0.8442                                              (0.23, 1.46)      0.930742
  C04   Galr1       Galanin receptor 1                                                        1.434                                               (0.35, 2.52)      0.323728
  C05   Gcg         Glucagon                                                                  0.7156                                              (0.50, 0.94)      0.065372
  C06   Gcgr        Glucagon receptor                                                         0.6864                                              (0.00001, 1.88)   0.15625
  C07   Gh          Growth hormone                                                            1.0612                                              (0.39, 1.73)      0.578551
  C08   Ghr         Growth hormone receptor                                                   0.8019                                              (0.52, 1.08)      0.199447
  C09   Ghrl        Ghrelin                                                                   0.5401                                              (0.21, 0.87)      0.133176
  C10   Ghsr        Growth hormone secretagogue receptor                                      1.3499                                              (0.00001, 3.00)   0.455813
  C11   Glp1r       Glucagon-like peptide 1 receptor                                          0.7071                                              (0.39, 1.03)      0.157053
  C12   Mchr1       Melanin-concentrating hormone receptor 1                                  1.3553                                              (0.00001, 2.95)   0.705335
  D01   Grp         Gastrin releasing peptide                                                 1.3526                                              (0.00001, 2.74)   0.919938
  D02   Grpr        Gastrin releasing peptide receptor                                        0.903                                               (0.38, 1.43)      0.278168
  D03   Hcrt        Hypocretin                                                                1.2483                                              (0.00001, 2.53)   0.509901
  D04   Hcrtr1      Hypocretin (orexin) receptor 1                                            0.5946                                              (0.34, 0.85)      0.051138
  D05   Hrh1        Histamine receptor H1                                                     1.6213                                              (0.56, 2.68)      0.239564
  D06   Htr2c       5-hydroxytryptamine (serotonin) receptor 2C                               1.005                                               (0.37, 1.64)      0.449317
  D07   Iapp        Islet amyloid polypeptide                                                 0.9238                                              (0.47, 1.37)      0.388305
  D08   Il1a        Interleukin 1 alpha                                                       0.6837                                              (0.06, 1.31)      0.257391
  D09   Il1b        Interleukin 1 beta                                                        1.879                                               (0.96, 2.80)      0.065358
  D10   Il1r1       Interleukin 1 receptor, type II                                           0.8671                                              (0.61, 1.13)      0.298529
  D11   Il6         Interleukin 6                                                             1.3906                                              (0.22, 2.56)      0.233615
  D12   Il6ra       Interleukin 6 receptor, alpha                                             1.022                                               (0.68, 1.37)      0.944864
  E01   Ins1        Insulin II                                                                1.3486                                              (0.00001, 2.93)   0.517016
  E02   Ins2        Insulin II                                                                0.7571                                              (0.54, 0.98)      0.109651
  E03   Insr        Insulin receptor                                                          0.6552                                              (0.36, 0.95)      0.119759
  E04   Lep         Leptin                                                                    1.2422                                              (0.50, 1.99)      0.223664
  E05   Lepr        Leptin receptor                                                           0.9284                                              (0.45, 1.41)      0.979422
  E06   Mc3r        Melanocortin 3 receptor                                                   0.9257                                              (0.47, 1.38)      0.390157
  E07   Nmb         Neuromedin B                                                              0.6029                                              (0.26, 0.95)      0.263443
  E08   Nmbr        Neuromedin B receptor                                                     0.5223                                              (0.07, 0.97)      0.293177
  E09   Nmu         Neuromedin U                                                              0.5917                                              (0.30, 0.88)      0.126651
  E10   Nmur1       Neuromedin U receptor 1                                                   0.6235                                              (0.00001, 1.34)   0.297705
  E11   Npy         Neuropeptide Y                                                            1.6439                                              (0.00001, 3.61)   0.820424
  E12   Npy1r       Neuropeptide Y receptor Y1                                                0.8459                                              (0.47, 1.22)      0.369206
  F01   Nr3c1       Nuclear receptor subfamily 3, group C, member 1                           0.7198                                              (0.57, 0.87)      0.008339
  F02   Ntrk2       Neurotrophic tyrosine kinase, receptor, type 2                            0.9004                                              (0.62, 1.19)      0.576791
  F03   Nts         Neurotensin                                                               1.4875                                              (0.00001, 3.75)   0.900008
  F04   Ntsr1       Neurotensin receptor 1                                                    1.1476                                              (0.49, 1.80)      0.700402
  F05   Oprk1       Opioid receptor, kappa 1                                                  0.8476                                              (0.54, 1.16)      0.283696
  F06   Oprm1       Opioid receptor, mu 1                                                     0.7586                                              (0.47, 1.05)      0.140887
  F07   Sigmar1     Sigma non-opioid intracellular receptor 1                                 0.7738                                              (0.61, 0.94)      0.034028
  F08   Pomc        Pro-opiomelanocortin-alpha                                                0.6988                                              (0.51, 0.89)      0.025299
  F09   Ppara       Peroxisome proliferator activated receptor alpha                          0.5285                                              (0.16, 0.90)      0.042418
  F10   Pparg       Peroxisome proliferator activated receptor gamma                          0.6199                                              (0.35, 0.89)      0.078419
  F11   Ppargc1a    Peroxisome proliferative activated receptor, gamma, coactivator 1 alpha   0.3884                                              (0.19, 0.59)      0.014167
  F12   Prlhr       Prolactin releasing hormone receptor                                      0.9367                                              (0.46, 1.41)      0.400798
  G01   Ptpn1       Protein tyrosine phosphatase, non-receptor type 1                         0.7908                                              (0.65, 0.93)      0.026759
  G02   Pyy         Peptide YY                                                                0.7489                                              (0.34, 1.16)      0.173387
  G03   Ramp3       Receptor (calcitonin) activity modifying protein 3                        1.188                                               (0.00001, 2.47)   0.620546
  G04   Sort1       Sortilin 1                                                                0.6481                                              (0.43, 0.87)      0.025804
  G05   Sst         Somatostatin                                                              0.7177                                              (0.50, 0.94)      0.066392
  G06   Sstr2       Somatostatin receptor 2                                                   0.732                                               (0.02, 1.44)      0.364054
  G07   Thrb        Thyroid hormone receptor beta                                             0.9442                                              (0.67, 1.22)      0.856009
  G08   Tnf         Tumor necrosis factor                                                     1.2758                                              (0.07, 2.49)      0.671972
  G09   Trh         Thyrotropin releasing hormone                                             0.77                                                (0.36, 1.18)      0.493715
  G10   Ucn         Urocortin                                                                 0.6571                                              (0.41, 0.91)      0.080877
  G11   Ucp1        Uncoupling protein 1 (mitochondrial, proton carrier)                      0.9574                                              (0.57, 1.35)      0.920895
  G12   Zfp91       Zinc finger protein 91                                                    0.856                                               (0.68, 1.03)      0.174067
  H01   Gusb        Glucuronidase, beta                                                       1.001                                               (0.64, 1.36)      0.781711
  H02   Hprt        Hypoxanthine guanine phosphoribosyl transferase                           0.8501                                              (0.70, 1.00)      0.110094
  H03   Hsp90ab1    Heat shock protein 90 alpha (cytosolic), class B member 1                 1.1052                                              (0.84, 1.37)      0.398062
  H04   Gapdh       Glyceraldehyde-3-phosphate dehydrogenase                                  0.8409                                              (0.65, 1.03)      0.147432
  H05   Actb        Actin, beta                                                               1.2645                                              (0.90, 1.63)      0.138857
  H06   MGDC        Mouse Genomic DNA Contamination                                           1.1151                                              (0.21, 2.02)      0.489386
  H07   RTC         Reverse Transcription Control                                             1.2311                                              (0.00, 2.46)      0.508164
  H08   RTC         Reverse Transcription Control                                             1.1544                                              (0.14, 2.17)      0.497475
  H09   RTC         Reverse Transcription Control                                             0.8228                                              (0.55, 1.10)      0.237255
  H10   PPC         Positive PCR Control                                                      0.9423                                              (0.46, 1.43)      0.405995
  H11   PPC         Positive PCR Control                                                      0.9564                                              (0.48, 1.43)      0.469732
  H12   PPC         Positive PCR Control                                                      0.9564                                              (0.44, 1.47)      0.4568

![The 3T3-L1 preadipocytes were cultured as previously described (Mihara M *et al.* Endocrinology. 2010; 151: 513--519.) and the cells plated onto six-well dishes were treated with thrombin (1 U/ml) or human purified heparin cofactor II (HCII) (100 nM) or dermatan sulfate (DS) (5 µg/ml) for 48 h. *n* = 6 in each group. NS means not significant.](jat-24-1215-g007){#F7}

HCII Insufficiency Reduces Phosphorylation of Akt and AMPK in the Adipose Tissue of Obese Mice
----------------------------------------------------------------------------------------------

We investigated the phosphorylation of AMPK in adipose tissues (epididymal fat tissue), liver, and skeletal muscle of *HCII*^+/+^ and *HCII*^+/−^ mice. Western blot analysis demonstrated that HFD-fed *HCII*^+/−^ mice had reduced the phosphorylation of AMPK in adipose tissue but not in the liver and skeletal muscle, compared with HFD-fed *HCII*^+/+^ mice (**[Fig. 4A](#F4){ref-type="fig"}** and [**Supplemental Figs. 3A** & **3B**](#F8){ref-type="fig"}). In addition to AMPK, we examined whether obese *HCII*^+/−^ mice have aberrant Akt phosphorylation in their adipose tissue, liver, and skeletal muscle. In the present study, HFD-fed *HCII*^+/−^ mice exhibited insufficient phosphorylation of Akt in adipose tissue but not in liver and skeletal muscle, compared to HFD-fed *HCII*^+/+^ mice (**[Fig. 4B](#F4){ref-type="fig"}** and [**Supplemental Figs. 3A** & **3B**](#F8){ref-type="fig"}). Moreover, we observed that insulin-stimulated phosphorylation of AMPK*α* and Akt in adipose tissue of HFD-treated *HCII*^+/−^ mice was also reduced compared to that in HFD-treated *HCII*^+/+^ mice ([**Figs. 4C** & **4D**](#F4){ref-type="fig"}). From these results, it is plausible to assume that both Akt and AMPK inactivation in the adipose tissue of *HCII*^+/−^ mice impair glucose transport and insulin action.

![Aberrant phosphorylation of insulin resistance-related factors\
Results of western blot analysis for GAPDH-adjusted phosphorylated AMPK (A) and phosphorylated Akt (B) in adipose tissues of *HCII*^+/+^ and *HCII*^+/−^ mice fed ND or HFD (*n* = 12 in each group). Results of western blot analysis for GAPDH-adjusted phosphorylated AMPK (C) and phosphorylated Akt (D) in the adipose tissues of *HCII*^+/+^ and *HCII*^+/−^ mice fed HFD after insulin injection (*n* = 9 in each group). \**p* \< 0.05, \*\**p* \< 0.01](jat-24-1215-g004){#F4}

![Quantitative results of phosphorylated AMPK-to-GAPDH protein ratios and phosphorylated Akt-to-GAPDH protein ratios in hepatic tissues and skeletal muscle (thigh) of *HCII*^+/+^ mice and *HCII*^+/−^ mice with ND or HFD feeding, *n* = 8 to 12 in each group. Bars represent mean values in each group. \**p* \< 0.05, NS means not significant.](jat-24-1215-g008){#F8}

HFD Enhances the Expression of Gluconeogenesis-Related Genes in *HCII*^+/−^ Mice
--------------------------------------------------------------------------------

Gluconeogenesis is regulated by the activity of two rate-limiting enzymes, phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6 Pase)^[@bib20])^. Therefore, we examined the expression levels of these genes in the liver, and found that mRNA levels of both *Pck1* (murine PEPCK homolog) and *G6pc* (murine G6 Pase homolog) in HFD-fed *HCII*^+/−^ mice were higher than those in HFD-fed *HCII*^+/+^ mice ([**Figs. 5A** and **5B**](#F5){ref-type="fig"}).

![Enhanced gene expression of gluconeogenesis-related factors in HFD-treated *HCII*^+/−^ mice\
Gene expression levels of *Pck1* (A) and *G6pc* (B) in hepatic tissues of *HCII*^+/+^ and *HCII*^+/−^ mice fed ND or HFD (*n* = 12 or 13 in each group). Bars represent the mean values in each group. \**p* \< 0.05, \*\**p* \< 0.01](jat-24-1215-g005){#F5}

Discussion
==========

In the present study, we provide the first evidence that plasma HCII activity is inversely associated with FPG, HbA1c, and HOMA-IR in humans. Furthermore, fasting hyperglycemia and prominent insulin resistance were more frequently found in HFD-fed *HCII*^+/−^ mice than that in HFD-fed *HCII*^+/+^ mice.

Obesity-induced glucose metabolism disorder is recognized as chronic low-grade systemic inflammation. Recently, molecular bases of metabolic inflammation and their potential pathogenic roles in diabetes and cardiovascular disease have been investigated^[@bib21]--[@bib23])^. Increasing evidence has revealed that the chemokine system is involved in chronic inflammation leading to obesity, insulin resistance, and T2DM. In this regard, MCP-1 is considered to play a pivotal role in obesity-induced insulin resistance^[@bib24])^. In our previous study, we found that *Mcp1* gene expression in 3T3-L1 adipocytes is markedly increased by thrombin treatment, suggesting that thrombin is a key molecule linking increased adiposity and an enhanced expression of MCP-1^[@bib8])^. In addition, we previously demonstrated that cuff injury of femoral arteries in *HCII*^+/−^ mice prominently augmented neointimal hyperplasia with the enhancement of vascular *Mcp1* gene expression^[@bib12])^. Therefore, HCII may be closely associated with the regulation of thrombin-MCP-1 axis.

TNF-*α* has also been recognized as a key molecule linking obesity and insulin resistance. Because TNF-*α* is overexpressed in the adipose tissue of obese animals and humans, and because obese mice lacking either TNF-*α* or its receptor have attenuated insulin resistance^[@bib25])^, it is plausible that the prominent gene expression of *tnf* was observed in HFD-treated *HCII*^+/−^ mice with insulin resistance. Moreover, Kalle *et al.* reported that *HCII*-deficient mice exhibit increased susceptibility to *Pseudomonas aeruginosa* infection with elevated inflammatory plasma cytokines such as interleukin 6, TNF-*α*, MCP-1, and interferon-*γ*^[@bib26])^. Their study suggested that HCII is an immunological regulator having broad anti-inflammatory effects. Taken together, these results are consistent with the notion that HCII deficiency promotes macrophage infiltration, leading to low-grade, chronic inflammation in adipose tissue.

In the present study, we found that *Cntfr* was significantly downregulated in *HCII*^+/−^ mice. CNTF is known to prevent obesity and ameliorate glucose tolerance. Watt *et al.* demonstrated that CNTF signals increase fatty acid oxidation and reduce insulin resistance via AMPK activation^[@bib27])^. Although we observed a reduced ratio of *Cntf* to *Cntfr* gene expression in HFD-treated *HCII*^+/−^ mice, the detailed mechanism underlying the influence of serine protease and/or its inhibitor on CNTF--CNTF receptor axis has been largely unknown. However, our *in vivo* and *in vitro* experimental results suggest that the aberrant balance between *Cntf* and *Cntfr* gene expression levels in *HCII*^+/−^ mice may be indirectly correlated with impaired AMPK activation. In addition, the finding of reduced phosphorylation of AMPK in HFD-treated *HCII*^+/−^ mice is consistent with the results of our previous study showing that HCII deficiency causes impaired AMPK phosphorylation in ischemic skeletal muscle, leading to insufficient angiogenic response^[@bib17])^. Thus, the present observations that reduced HCII activity leads to AMPK inactivation in adipose tissue may at least partly explain why *HCII*^+/−^ mice with HFD-induced obesity developed insulin resistance.

The serine/threonine protein kinase Akt is strongly associated with the homeostatic regulation of glucose metabolism^[@bib28])^. Targeted disruption of PKB*β*, an Akt isoform, in mice diminished the insulin-stimulated glucose uptake in muscle and adipocytes, and the dysregulation of hepatic glucose production^[@bib29])^. As our previous study provided evidence that thrombin stimulation blunts Akt phosphorylation in 3T3L-1 adipocytes^[@bib8])^, we evaluated Akt phosphorylation in the adipose tissue of mice and found that HCII deficiency causes insufficient activation of Akt in HFD-induced obesity. It has been demonstrated that macrophage infiltration and secreted factors from the macrophages in adipocytes inhibit Akt phosphorylation, subsequently impairing insulin action^[@bib30])^. The enhancement of macrophage infiltration along with increased gene expression of *Mcp1* induced by HCII deficiency may partially explain Akt inactivation. From these results, it is plausible to assume that Akt inactivation, along with AMPK inactivation, in the adipose tissue of *HCII*^+/−^ mice impair glucose transport and insulin action.

Gluconeogenesis is one of the major mechanisms to maintain blood glucose levels and prevent hypoglycemia. The acceleration of gluconeogenesis in the liver is largely responsible for fasting hyperglycemia in patients with T2DM^[@bib31])^. Gluconeogenesis is regulated by the activity of two rate-limiting enzymes, PEPCK and G6 Pase^[@bib20])^. Therefore, we evaluated the expression levels of these genes in the liver, and found that the mRNA levels of both *Pck1* (murine PEPCK homologue) and *G6pc* (murine G6 Pase homologue) in HFD-fed *HCII*^+/−^ mice were higher than those in HFD-fed *HCII*^+/+^ mice. Previous studies showed that thrombin activates NAD(P)H oxidase; oxidative stress is known to be associated with increased expression of PEPCK and G6 Pase. Thus, it is possible that HCII deficiency augments oxidative stress by activating the tissue thrombin-PAR-1 axis and enhances PEPCK and G6 Pase expression, leading to fasting hyperglycemia.

Oxidative stress and chronic inflammation are known to be associated with the development of metabolic diseases, including obesity and diabetes^[@bib32])^. Because we previously reported that *HCII*^+/−^ mice manifest excessive superoxide production at the sites of vascular injury, the observed glucose metabolism disorder in the present study may be associated with an abnormal oxidative stress state in HFD-treated *HCII*^+/−^ mice.

As thrombin inactivation is effectively caused by complex formation with HCII and dermatan sulfate (DS), DS has an important role in the modulation of thrombin action. Because glycosaminoglycans (GAGs) undergo structural and functional remodeling in various pathological states including hyperglycemia and the levels of GAGs such as chondroitin/DS are significantly decreased in diabetic condition^[@bib33],\ [@bib34])^, the amount and functional changes of DS may be associated with thrombin inhibition by HCII.

In conclusion, the present study provides evidence supporting the assumption that HCII, a serine protease inhibitor, plays an important role in maintaining glucose homeostasis by regulating insulin sensitivity in both humans and mice. Our findings suggest that the measurement of plasma HCII activity may be useful for identifying patients at high risk for T2DM and cardiovascular complications. In addition, the stimulation of HCII production may be a novel therapeutic approach to ameliorate cardiovascular diseases and diabetic conditions in patients with T2DM.
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